Keybank National Association OH boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 119.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,695 shares of the biotechnology company’s stock after purchasing an additional 5,812 shares during the quarter. Keybank National Association OH’s holdings in BioMarin Pharmaceutical were worth $1,007,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BMRN. Bronfman E.L. Rothschild L.P. lifted its holdings in BioMarin Pharmaceutical by 19.5% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 7,147 shares of the biotechnology company’s stock worth $673,000 after purchasing an additional 1,164 shares during the period. US Bancorp DE lifted its holdings in BioMarin Pharmaceutical by 5.6% in the second quarter. US Bancorp DE now owns 10,851 shares of the biotechnology company’s stock worth $1,021,000 after purchasing an additional 576 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in BioMarin Pharmaceutical by 5.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 375,366 shares of the biotechnology company’s stock worth $35,360,000 after purchasing an additional 20,685 shares during the period. Bailard Inc. lifted its holdings in BioMarin Pharmaceutical by 25.0% in the second quarter. Bailard Inc. now owns 5,000 shares of the biotechnology company’s stock worth $471,000 after purchasing an additional 1,000 shares during the period. Finally, Nissay Asset Management Corp Japan ADV lifted its holdings in BioMarin Pharmaceutical by 4.8% in the second quarter. Nissay Asset Management Corp Japan ADV now owns 12,078 shares of the biotechnology company’s stock worth $1,138,000 after purchasing an additional 556 shares during the period.

Shares of BioMarin Pharmaceutical stock opened at $98.92 on Wednesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.24 and a current ratio of 2.83. BioMarin Pharmaceutical Inc. has a 52 week low of $75.81 and a 52 week high of $106.20.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). BioMarin Pharmaceutical had a negative return on equity of 3.00% and a negative net margin of 8.68%. The business had revenue of $372.80 million during the quarter, compared to the consensus estimate of $359.25 million. During the same quarter last year, the firm posted ($0.21) earnings per share. BioMarin Pharmaceutical’s revenue was up 17.4% compared to the same quarter last year. sell-side analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.24 earnings per share for the current year.

Several research firms recently weighed in on BMRN. BidaskClub raised shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Citigroup upped their price objective on shares of BioMarin Pharmaceutical from $108.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. ValuEngine raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Thursday, July 12th. Stifel Nicolaus upped their price objective on shares of BioMarin Pharmaceutical from $102.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Finally, Morgan Stanley upped their price objective on shares of BioMarin Pharmaceutical from $113.00 to $115.00 and gave the stock an “overweight” rating in a report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $116.28.

In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 31,000 shares of the business’s stock in a transaction dated Thursday, June 14th. The stock was sold at an average price of $90.00, for a total transaction of $2,790,000.00. Following the sale, the insider now owns 157,167 shares in the company, valued at approximately $14,145,030. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Alan Lewis sold 4,200 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $100.09, for a total value of $420,378.00. Following the sale, the director now owns 21,160 shares in the company, valued at approximately $2,117,904.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 107,574 shares of company stock worth $10,404,944. 1.90% of the stock is owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Read More: Outstanding Shares

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.